Chapter 10. Immunomodulating Therapy in Chronic Heart Failure

  1. Ronald Ross Watson1,2 and
  2. Douglas F. Larson3
  1. Lars Gullestad,
  2. Jan Kristian Damås,
  3. Arne Yndestad and
  4. Pål Aukrust

Published Online: 15 APR 2008

DOI: 10.1002/9780470692325.ch10

Immune Dysfunction and Immunotherapy in Heart Disease

Immune Dysfunction and Immunotherapy in Heart Disease

How to Cite

Gullestad, L., Damås, J. K., Yndestad, A. and Aukrust, P. (2007) Immunomodulating Therapy in Chronic Heart Failure, in Immune Dysfunction and Immunotherapy in Heart Disease (eds R. R. Watson and D. F. Larson), Blackwell Publishing Ltd, Oxford, UK. doi: 10.1002/9780470692325.ch10

Editor Information

  1. 1

    Department of Nutritional Sciences, The University of Arizona; and Sarver Heart Center, College of Medicine, The University of Arizona

  2. 2

    Division of Health Promotion Sciences, Mel and Enid Zuckerman Arizona College of Public Health, The University of Arizona Tucson, AZ USA

  3. 3

    Sarver Heart Center College of Medicine The University of Arizona Tucson, AZ USA

Publication History

  1. Published Online: 15 APR 2008
  2. Published Print: 30 AUG 2007

ISBN Information

Print ISBN: 9781405155687

Online ISBN: 9780470692325

SEARCH

Keywords:

  • immunomodulating therapy;
  • heart failure;
  • plasma;
  • cardiovascular drugs;
  • cytokines

Summary

This chapter contains section titled:

  • Overview

  • Introduction

  • Rationale for immunomodulating therapy

  • Pathophysiological consequences of immune activation in HF

  • Immunomodulating therapy

  • Targeted anticytokine therapy

  • Why did the anti-TNF therapy fail?

  • Nonspecific immunomodulating therapy

  • New therapeutic targets in HF

  • Conclusions

  • References